Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Li, Hong ^a   Zhang, Xiaoyun ^a   Guan, Xiumei ^a   Cui, Xiaodong ^a   Wang, Yuliang ^a   Chu, Hairong ^a   Cheng, Min ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Ages; Diabetes; Endothelial progenitor cells; Vasoactive substances

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CD31 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; STROMAL CELL DERIVED FACTOR 1; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; CXCR4 PROTEIN, RAT;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DISEASE COURSE; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR DISEASE; WESTERN BLOTTING; ANIMAL; CELL MOTION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; STEM CELL;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL12; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOPROSTENOL; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84862161932     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-46     Document Type: Article

References (52)

1. Heller GV. Evaluation of the patient with diabetes mellitus and suspected coronary artery disease. Am J Med 2005, 118(Suppl 2):9S-14S.
2. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001, 49(3):554-560. 10.1016/S0008-6363(00)00228-5, 11166268.
3. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105(25):3017-3024. 10.1161/01.CIR.0000018166.84319.55, 12081997.
4. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002, 22(10):1567-1572. 10.1161/01.ATV.0000036417.43987.D8, 12377731.
5. Naito H, Kidoya H, Sakimoto S, Wakabayashi T, Takakura N. Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J 2012, 31(4):842-855.
6. Rohde E, Malischnik C, Thaler D, Maierhofer T, Linkesch W, Lanzer G, Guelly C, Strunk D. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006, 24(2):357-367. 10.1634/stemcells.2005-0072, 16141361.
7. Brown MA, Wallace CS, Angelos M, Truskey GA. Characterization of umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to laminar shear stress. Tissue Eng Part A 2009, 15(11):3575-3587. 10.1089/ten.tea.2008.0444, 2792062, 19480571.
8. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004, 24(2):288-293.
9. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004, 53(1):195-199.
10. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106(22):2781-2786. 10.1161/01.CIR.0000039526.42991.93, 12451003.
11. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008, 51(6):660-668. 10.1016/j.jacc.2007.09.059, 18261686.
12. Kawabe-Yako R, Masaaki I, Masuo O, Asahara T, Itakura T. Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. PLoS One 2011, 6(9):e24646. 10.1371/journal.pone.0024646, 3171459, 21931795.
13. Moriyama T, Kemi M, Okumura C, Yoshihara K, Horie T. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats. Toxicology 2010, 268(1-2):89-97.
14. Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol 2008, 35(3):329-334. 10.1111/j.1440-1681.2007.04875.x, 18290873.
15. Stitt AW, Hughes SJ, Canning P, Lynch O, Cox O, Frizzell N, Thorpe SR, Cotter TG, Curtis TM, Gardiner TA. Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 2004, 47(10):1735-1746. 10.1007/s00125-004-1523-3, 15502926.
16. Chen J, Song M, Yu S, Gao P, Yu Y, Wang H, Huang L. Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol Cell Biochem 2010, 335(1-2):137-146.
17. Chen Q, Dong L, Wang L, Kang L, Xu B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun 2009, 381(2):192-197. 10.1016/j.bbrc.2009.02.040, 19232321.
18. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005, 39(5):733-742. 10.1016/j.yjmcc.2005.07.003, 16199052.
19. Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, Liu PL, Chen YL, Chen JW. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007, 56(6):1559-1568. 10.2337/db06-1103, 17389326.
20. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003, 17(10):1289-1291.
21. Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, Zhen Y, Fan M, Wu Z. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 2009, 158(8):1865-1873. 10.1111/j.1476-5381.2009.00450.x, 2807648, 19917066.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
23. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000, 7(3):169-176.
24. Bro S, Flyvbjerg A, Binder CJ, Bang CA, Denner L, Olgaard K, Nielsen LB. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 2008, 201(2):274-280. 10.1016/j.atherosclerosis.2008.01.015, 18371970.
25. Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes-part II: cellular mechanisms and therapeutic targets. Vascul Pharmacol 2011, 54(3-6):75-79.
26. Zhou YJ, Yang HW, Wang XG, Zhang H. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells. Life Sci 2009, 85(19-20):670-677.
27. Palombo C, Kozakova M, Morizzo C, Gnesi L, Barsotti MC, Spontoni P, Massart F, Salvi P, Balbarini A, Saggese G, et al. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. Cardiovasc Diabetol 2011, 10:88. 10.1186/1475-2840-10-88, 3198903, 21981808.
28. Bozdag-Turan I, Turan RG, Turan CH, Ludovicy S, Akin I, Kische S, Arsoy NS, Schneider H, Ortak J, Rehders T, et al. Relation between the frequency of CD34 bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes. Cardiovasc Diabetol 2011, 10:107. 10.1186/1475-2840-10-107, 3235974, 22118372.
29. Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2011, 10:113. 10.1186/1475-2840-10-113, 3258289, 22185563.
30. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Koide H, Ueda Y, Takeuchi M, Yamagishi S. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin Cardiol 2011, 34(6):372-377. 10.1002/clc.20885, 21432860.
31. Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, Ohsaka H, Matsumori R, Kurata T, Miyazaki T, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function - a crossover trial (AGENT). Cardiovasc Diabetol 2011, 10:79. 10.1186/1475-2840-10-79, 3179711, 21906391.
32. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009, 104(1):42-49. 10.1007/s00395-008-0738-8, 18622638.
33. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 2006, 34(8):967-975. 10.1016/j.exphem.2006.04.002, 16863903.
34. Giebel B, Corbeil D, Beckmann J, Hohn J, Freund D, Giesen K, Fischer J, Kogler G, Wernet P. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004, 104(8):2332-2338. 10.1182/blood-2004-02-0511, 15231568.
35. Vagima Y, Lapid K, Kollet O, Goichberg P, Alon R, Lapidot T. Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods Mol Biol 2011, 750:277-289. 10.1007/978-1-61779-145-1_19, 21618098.
36. Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, Bieche I, Laurendeau I, Galy-Fauroux I, Fischer AM, Boisson-Vidal C. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008, 28(4):644-650. 10.1161/ATVBAHA.107.160044, 18239152.
37. Smadja DM, Bieche I, Uzan G, Bompais H, Muller L, Boisson-Vidal C, Vidaud M, Aiach M, Gaussem P. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system. Arterioscler Thromb Vasc Biol 2005, 25(11):2321-2327. 10.1161/01.ATV.0000184762.63888.bd, 16141404.
38. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001, 108(9):1341-1348. 209429, 11696579.
39. Ozuyaman B, Ebner P, Niesler U, Ziemann J, Kleinbongard P, Jax T, Godecke A, Kelm M, Kalka C. Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells. Thromb Haemost 2005, 94(4):770-772.
40. Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, Beem E, Shaw LC, Li Calzi S, Harrison JK, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006, 55(1):102-109. 10.2337/diabetes.55.01.06.db05-0803, 16380482.
41. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, Nedeau A, Thom SR, Velazquez OC. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007, 117(5):1249-1259. 10.1172/JCI29710, 1857264, 17476357.
42. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006, 98(11):1405-1413. 10.1161/01.RES.0000224117.59417.f3, 16645141.
43. Kawabe J, Yuhki K, Okada M, Kanno T, Yamauchi A, Tashiro N, Sasaki T, Okumura S, Nakagawa N, Aburakawa Y, et al. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol 2010, 30(3):464-470. 10.1161/ATVBAHA.109.193730, 20007911.
44. Dandona P. Vascular reactivity in diabetes mellitus. Endocrinologia y nutricion: organo de la Sociedad Espanola de Endocrinologia y Nutricion 2009, 56(Suppl 4):12-14.
45. Iwase E, Tawata M, Aida K, Ozaki Y, Kume S, Satoh K, Qi R, Onaya T. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. Metabolism 1998, 47(6):699-705. 10.1016/S0026-0495(98)90034-8, 9627370.
46. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 2005, 96(8):818-822. 10.1161/01.RES.0000163631.07205.fb, 15860762.
47. He T, Peterson TE, Holmuhamedov EL, Terzic A, Caplice NM, Oberley LW, Katusic ZS. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol 2004, 24(11):2021-2027. 10.1161/01.ATV.0000142810.27849.8f, 15319267.
48. Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, Widder JD, Tsikas D, Ertl G, Bauersachs J. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007, 56(3):666-674. 10.2337/db06-0699, 17327434.
49. Turkseven S, Kruger A, Mingone CJ, Kaminski P, Inaba M, Rodella LF, Ikehara S, Wolin MS, Abraham NG. Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 2005, 289(2):H701-H707. 10.1152/ajpheart.00024.2005, 15821039.
50. Hamed S, Brenner B, Aharon A, Daoud D, Roguin A. Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus. Cardiovasc Diabetol 2009, 8:56. 10.1186/1475-2840-8-56, 2773759, 19878539.
51. Hanke H, Lenz C, Finking G. The discovery of the pathophysiological aspects of atherosclerosis-a review. Acta Chir Belg 2001, 101(4):162-169.
52. Shirota T, He H, Yasui H, Matsuda T. Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing. Tissue Eng 2003, 9(1):127-136. 10.1089/107632703762687609, 12625961.